NFE2L2 and diabetes mellitus: Additionally, analog of the NRF2 agonist bardoxolone methyl, dh404, at a lower dose significantly lessens diabetes-associated atherosclerosis with reductions in oxidative stress and proinflammatory mediators tumor necrosis factor-α, intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and monocyte chemotactic protein-1 (MCP-1) in streptozotocin induced diabetic apolipoprotein E(−/−) mice.